Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease | Zendy

Oliver Distler | Zendy; Kristin B. Highland | Zendy; Martina Gahlemann | Zendy; Arata Azuma | Zendy; Aryeh Fischer | Zendy; Maureen D. Mayes | Zendy; Ganesh Raghu | Zendy; Wiebke Sauter | Zendy; M Girard | Zendy; Margarida Alves | Zendy; Emmanuelle Clerisme-Beaty | Zendy; Susanne Stowasser | Zendy; Kay Tetzlaff | Zendy; Masataka Kuwana | Zendy; Toby M. Maher | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

Author(s) -

Oliver Distler,

Kristin B. Highland,

Martina Gahlemann,

Arata Azuma,

Aryeh Fischer,

Maureen D. Mayes,

Ganesh Raghu,

Wiebke Sauter,

M Girard,

Margarida Alves,

Emmanuelle Clerisme-Beaty,

Susanne Stowasser,

Kay Tetzlaff,

Masataka Kuwana,

Toby M. Maher

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1903076

Subject(s) - nintedanib , interstitial lung disease , medicine , scleroderma (fungus) , lung , idiopathic pulmonary fibrosis , pathology , inoculation

Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ILD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research